Form 4: Boundless Bio Director Christine Brennan Granted Stock Options

Boundless Bio, Inc. director Christine Brennan was granted 16,000 stock options with an exercise price of $1.03, vesting over 12 months.

Summary

• Christine Brennan, a Director of Boundless Bio, Inc. (BOLD), was granted 16,000 stock options.
• The transaction date for this grant was June 23, 2025.
• The exercise price for these stock options is $1.03 per share.
• The options will vest in substantially equal monthly installments over the 12 months following June 23, 2025.
• Alternatively, any remaining unvested portion will vest on the date of the next annual meeting of the issuer's stockholders if it occurs prior to June 23, 2026.
• Vesting is contingent upon Ms. Brennan's continued service on the issuer's board of directors through the vesting date.
• The expiration date for these stock options is June 22, 2035.
• Following this transaction, Christine Brennan beneficially owns 16,000 derivative securities (stock options) and 16,000 underlying common stock shares.

Sentiment

Score: 6

Explanation: The document reports a standard, expected compensation event for a director, which is generally a neutral to slightly positive signal as it aligns interests, but does not contain significant new financial or operational information.

Positives

• The grant of stock options aligns the director's financial interests with those of the shareholders, incentivizing long-term value creation.
• This represents standard equity compensation for a director, indicating ongoing commitment and engagement with the company.

Risks

• The value of the stock options is dependent on the future market price of Boundless Bio, Inc. common stock exceeding the exercise price of $1.03.
• The options are subject to a vesting schedule, meaning the director must continue service on the board for the options to fully vest.

Future Outlook

The vesting schedule of the stock options over the next 12 months indicates an expectation of continued service by Christine Brennan on the board of directors, aligning her long-term interests with the company's performance.

Industry Context

The granting of stock options to directors is a common practice in publicly traded companies, particularly in the biotechnology sector, to attract and retain experienced board members and align their interests with shareholder value creation.

Comparison to Industry Standards

• Granting stock options as part of director compensation is a standard practice across various industries, including biotechnology, to incentivize long-term commitment and performance.
• The vesting schedule tied to continued service is typical for such equity awards, ensuring ongoing engagement from board members.

Corporate Governance

Related Party Transactions

• The stock option grant to Christine Brennan, a director, constitutes a related party transaction, which is a standard component of director compensation.

Stakeholder Impact

• Shareholders: The grant aims to align the director's interests with shareholders, potentially leading to better long-term decision-making and value creation.
• Employees: No direct impact mentioned, but a well-governed company can indirectly benefit all stakeholders.

Next Steps

• Christine Brennan's continued service on the Boundless Bio, Inc. board of directors to ensure full vesting of the stock options.
• Potential exercise of options by Christine Brennan upon vesting and favorable stock price movement.

Key Dates

Keywords

SEC Form 4, Stock Option Grant, Director Compensation, Insider Transaction, Equity Compensation, Boundless Bio, BOLD